Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

COX-2 Inhibitor Therapy: Potential Relevance as Cancer Treatment?
Author
Howard (Jack) West, MD

We'll break from brain metastases for a while to talk about another potential avenue of targeted therapy in lung cancer: the cyclo-oxygenase, or COX, pathway.

Cyclo-oxygenase (COX) inhibition has been studied as a potential mechanism for inhibiting cancer over the past few years, and recently some early clinical trial results have looked promising and generated a great deal of enthusiasm. A central component of the arachadonic acid pathway (complicated, and not on the quiz, so don't worry about it unless very motivated), COX is an enzyme found in two common forms, COX-1 and COX-2. COX-1 is constitutively expressed, which means it is present routinely in normal cells and plays a part in many routine cellular functions, among them helping to maintain the gastrointestinal (GI) mucosa. In contrast, COX-2 is an inducible enzyme, meaning that it is expressed selectively in the setting of signals that trigger inflammation as well as cancer development. Non-steroidal anti-inflammatory drugs (NSAIDs), your basic naproxen or ibuprofen, block both COX-1 and COX-2, and they can effectively reduce pain in the setting of inflammation, which is why they are taken for back pain and muscle aches, etc. Unfortunately, they can block some of the normal activities of platelets, which are important in clotting when you need to, and they can harm the stomach lining and lead to ulcers (remember that COX-1 helps maintain the stomach lining) and GI bleeding, which is uncommon but definitely seen with NSAIDs. COX-2 inhibitors, in contrast, have the potential to block inflammatory effects without the detrimental effects on platelet function or stomach lining. Here's a pretty detailed diagram:

COX pathways slide (click to enlarge)

As you probably know from watching the news in the last few years, COX-2 inhibitors don't appear to be toxicity-free, either. Rofecoxib (Vioxx) was taken off of the US market after initial FDA approval based on findings of increased cardiac events (summarized here), and there have also been reports about similar increases in cardiovascular events among people who received celecoxib (Celebrex) (abstract here).

Why are we talking about medicines for musculoskeletal pain here? Because COX-2 may be relevant in the development of, and treatment of, cancer. For starters, I mentioned that it isn't seen in normal tissues, but it's present on many different types of cancers, including NSCLC.

COX2 tumor staining

Lab studies also show that COX-2 expression leads to several advantages for tumor cells, including promoting angiogenesis (increased blood supply to the tumor), inhibiting apoptosis (programmed cell death that could otherwise auto-destruct a dysfunctional cell), and increasing adhesion to the extracellular matrix (which promotes invasion and metastatic tumor spread). These are all bad things, and in fact, blocking COX-2 can have anti-angiogenic properties, reverses growth of pre-malignant colon polyps that otherwise grow to become colon cancer in patients with a familial high-risk syndrome (abstract here), and inhibits tumor cell growth in many test tube and animal models.

In actual humans, it also appears that high COX-2 expression of NSCLC tumors is associated with worse outcomes. One early trial from Japan (abstract here) looked at 130 lung adenocarcinomas and found that survival was better for the patients with low COX-2 expression, and this result was particularly seen for patients with stage I tumors:

COX Achiwa Clin Cancer Res 1999

Another study from the US by a brilliant young oncologist named West (abstract here) revealed that stage I NSCLC tumors that recurred were significantly more likely to have high COX-2 expression than the stage I tumors that did not recur, and that overall stage I tumors were less likely to have high COX-2 expression than stage IV tumors:

COX2 expression stage I recurrence rate West COX2 West stage I vs Stage IV

And while not statistically significant with the small numbers tested (total of 28 stage IV tumors), the median survival for stage IV patients who had tumors without COX-2 expression was 19 months, vs. 10.7 months for those with COX-2 positive tumors. And other groups have also found this association of better survival in patients with tumors showing low COX-2 expression (abstract here, another here):

COX2 Brabender Clin Cancer Res

Fair to say, then, that COX-2 expression is associated with worse outcomes in cancer, particularly lung cancer, and that we've seen that celebrex can reverse precancerous polyps that lead to colon cancer. But do celebrex or other COX-2 inhibitors provide a treatment benefit in lung cancer? We'll examine studies combining celebrex with both chemo and EGFR inhibitor therapies next.

Next Previous link

Previous PostNext Post

Related Content

Image
Bladder Cancer Video Library 2024
Video
Dr. Petros Grivas discusses intravesical treatment for patients with nonmuscle invasive, or early-stage, bladder cancer, the importance of participating in clinical trials for bladder cancer, combination therapy options for patients with metastatic or incurable bladder cancer, and the importance of family history of cancer and discussing that history with your doctor.
Image
Case Based Panel
Video
The panel discusses treatment options for a patient diagnosed with EGFR Exon 19 Deletion NSCLC and examines data from the Laura Trial, a patient with a smoking history and diagnosis of small cell lung cancer, and how the Adriatic Study factors into decisions, and a patient with NSCLC adenocarcinoma, and a EGFR Exon 21 L858R Alteration, and how data from the Flaura 2 Trial can impact treatment decisions.
Image
Terapias Dirigidas de Cancer de Pulmón 2024
Video
La Dra. Estelamari Rodríguez presenta información básica sobre el NSCLC EGFR+ y analiza la importancia de las pruebas de biomarcadores en el cáncer de pulmón y ofrece una descripción general de las opciones de tratamiento para la enfermedad EGFR+.  Para ver la playlist completa, de click aquí.        

Forum Discussions

Hello Linda, my name is Alexandra Beneke, I'm the Outreach Manager for GRACE. Your willingness to share your experiences and knowledge with the cancer community is truly inspiring. Your dedication to...

Hi Bluebird,  Welcome to GRACE.  I'm sorry you're going through this scare and hope it's just inflammation or from an infection you didn't know you had. 

 

A CT would be...

Radiation + Brain Operation has just been discarded due to high risk. They will double Tagrisso dosis and then wait to see if it works, then try traditional Chemo. I would...

Hi and welcome to GRACE.  I'm sorry to know you are entering a new stage.  I'm not about to comment just now but wanted to let you know I see your...

Edit to say, we can't give advice but we can comment with views and facts.  :)

 

My first thought is to ask if she has been seen at a large...

Hi Barbro, Welcome to GRACE. I'm sorry you're worrying about this. We aren't able to give feedback on scan reports. Interpreting scan reports in this setting is not only unethical but...

Recent Comments

JOIN THE CONVERSATION
Tagrix FDA Approval
By mariachristian on
Hi Judy! It is so good to…
By JanineT GRACE … on
Tagrix vs Tagrisso
By Dipakchavan on
Hello Linda, my name is…
By AlexandraGBeneke on